METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Tracking advanced prostate cancer treatment in real patients
Disease control OngoingThis study observes how well apalutamide controls prostate cancer in real-world patients who have already chosen this treatment with their doctor. Researchers will track 170 men with metastatic prostate cancer that still responds to hormone therapy, monitoring their PSA levels an…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Targeted prostate cancer trial for hispanic and black men withdrawn before start
Disease control TerminatedThis study aimed to test a combination of two drugs, niraparib and abiraterone, plus a steroid, in men with newly diagnosed, advanced prostate cancer that had spread and had specific genetic changes. It specifically sought Hispanic/Latino and non-Hispanic Black participants to se…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE2 • Sponsor: Qian Qin • Aim: Disease control
Last updated Mar 09, 2026 14:23 UTC
-
New scan study aims to Fine-Tune prostate cancer care
Knowledge-focused OngoingThis study is testing whether a type of advanced scan called PSMA-PET can be used to monitor how well treatment is working for men with metastatic prostate cancer that responds to hormone therapy. Twenty participants will receive standard treatment and undergo two of these scans—…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:19 UTC
-
Scientists probe if common prostate cancer drugs make tumors 'Glow' brighter on scans
Knowledge-focused OngoingThis small, early study aims to understand if standard hormone therapy drugs change how prostate cancer appears on a specialized PSMA PET scan. About 15 men with recurrent prostate cancer will receive a standard hormone pill and have two scans over four weeks. The goal is to gath…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: EARLY_PHASE1 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Knowledge-focused
Last updated Mar 17, 2026 12:55 UTC
-
Real-World heart safety check for prostate cancer drug
Knowledge-focused OngoingThis study is collecting safety information on an approved prostate cancer drug combination in real-world medical practice. It will follow about 100 Japanese men with advanced prostate cancer that has spread and is still sensitive to hormone therapy. The main goal is to monitor f…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Mar 11, 2026 14:53 UTC